Bath-PUVA therapy decreases infiltrating CCR4-expressing tumor cells and regulatory T cells in patients with mycosis Fungoides.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Clinical Lymphoma, Myeloma & Leukemia

• Publication date

  2013-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.clml.2012.12.002PMID 23332394
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.

  2010cited by this paper
• Defucosylated Humanized Anti-CCR4 Monoclonal Antibody KW-0761 as a Novel Immunotherapeutic Agent for Adult T-cell Leukemia/Lymphoma

  2010cited by this paper
• Bath-PUVA therapy induces circulating regulatory T cells in patients with psoriasis.

  2009cited by this paper
• Phenotypic and Functional Analysis of CD4+CD25−Foxp3+ T Cells in Patients with Systemic Lupus Erythematosus1

  2009cited by this paper
• Extracorporeal photochemotherapy.

  2009cited by this paper
• Cutaneous Lymphomas and Lymphocytic Infiltrates

  2008cited by this paper
• In vivo expansion of CD4+Foxp3+ regulatory T cells mediated by GITR molecules.

  2008cited by this paper
• Narrow‐band ultraviolet therapy in early‐stage mycosis fungoides: study on 20 patients

  2007cited by this paper
• FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival

  2007cited by this paper
• CCR4 as a novel molecular target for immunotherapy of cancer

  2006cited by this paper
• Regulatory T cells.

  2006cited by this paper
• Bath-water PUVA therapy with 8-methoxypsoralen in mycosis fungoides.

  2005cited by this paper
• CXC Chemokine Receptor 3 and CC Chemokine Receptor 4 Expression in T-Cell and NK-Cell Lymphomas with Special Reference to Clinicopathological Significance for Peripheral T-Cell Lymphoma, Unspecified

  2004cited by this paper
• Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells.

  2004cited by this paper
• The pathogenesis of mycosis fungoides.

  2004cited by this paper
• Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome.

  2003cited by this paper
• Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides.

  2003cited by this paper
• Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

  2003cited by this paper
• Unique Chemotactic Response Profile and Specific Expression of Chemokine Receptors Ccr4 and Ccr8 by Cd4+Cd25+ Regulatory T Cells

  2001cited by this paper
• Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity.

  2001cited by this paper
• Induction of human tumor‐loaded dendritic cells

  2001cited by this paper
• Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients.

  2000cited by this paper
• Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine.

  1999cited by this paper
• 312-nanometer Ultraviolet B Light (Narrow-Band UVB) Induces Apoptosis of  T Cells within Psoriatic Lesions

  1999cited by this paper
• Topical corticosteroids for mycosis fungoides. Experience in 79 patients.

  1998cited by this paper
• The T Cell-directed CC Chemokine TARC Is a Highly Specific Biological Ligand for CC Chemokine Receptor 4*

  1997cited by this paper
• Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Clinical and prognostic implications.

  1996cited by this paper
• Conformational changes in mouse MHC class II proteins at acidic pH.

  1992cited by this paper
• Treatment of a Case of Mycosis Fungoides and One of Parapsoriasis en Plaque with Topical PUVA Using a Monofunctional Furocoumarin Derivative, 4,6,4'‐Trimethylangelicin

  1990cited by this paper
• Cutaneous T cell Lymphoma

  1987cited by this paper
• Dohi memorial lecture. Cutaneous T cell lymphoma.

  1987cited by this paper
• Cutaneous T cell lymphoma associated with recurrent panniculitis and reactive histiocytosis.

  1981cited by this paper

• Japanese Dermatological Association Guidelines: Outlines of Japanese Guidelines for the Management of Primary Cutaneous Lymphomas 2025

  2025cites this paper
• Folliculotropic mycosis fungoides successfully treated with bath psoralen plus ultraviolet a therapy

  2022cites this paper
• Efficacy of bath‐psoralen and ultraviolet A therapy for mycosis fungoides – retrospective analysis of 62 cases

  2021cites this paper
• Effectiveness and Safety of Topical Phototherapy in the Treatment of Dermatological Diseases

  2017cites this paper
• Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium.

  2016cites this paper
• STAT3/5-Dependent IL9 Overexpression Contributes to Neoplastic Cell Survival in Mycosis Fungoides

  2016influential citation
• Psoralen–ultraviolet A endures as one of the most powerful treatments in dermatology: reinforcement of this ‘triple‐product therapy’ by the 2016 British guidelines

  2016cites this paper
• Successful treatment of subcutaneous granuloma annulare with bath‐psoralen plus ultraviolet A therapy

  2015cites this paper
• Phototherapy for mycosis fungoides.

  2015cites this paper
• Role of bath psoralen plus ultraviolet A in early-stage mycosis fungoides.

  2014cites this paper
• Bath vs. oral psoralen plus ultraviolet A: is one more effective than the other?

  2013cites this paper